Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company that develops novel small-molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in a Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It provides data from the first Phase 3 clinical trial, THRIVE-AA1, to form the basis of a new drug application. The company was incorporated in 2006 and is based in Lexington, Massachusetts. As of March 6, 2023, Concert Pharmaceuticals, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited.